Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles

Details

Serval ID
serval:BIB_BC74FFFA93E7
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles
Journal
International Journal of Pharmaceutics
Author(s)
Cirstoiu-Hapca  A., Bossy-Nobs  L., Buchegger  F., Gurny  R., Delie  F.
ISSN
0378-5173 (Print)
Publication state
Published
Issued date
03/2007
Volume
331
Number
2
Pages
190-6
Notes
Journal Article --- Old month value: Mar 1
Abstract
Two types of antibody-labeled nanoparticles (mAb-NPs) were prepared with the aim to achieve specific tumor targeting. Anti-HER2 and anti-CD20 monoclonal antibodies (mAb) were used as model ligands. Small poly(dl-lactic acid) nanoparticles (PLA NPs) with a mean size of about 170 nm were prepared by the salting out method. Thereafter, the coating of PLA NPs with mAbs was performed in two steps. First, thiol groups (-SH) were introduced on the surface of PLA-NPs by a two-step carbodiimide reaction. The number of -SH groups on the surface of NPs increased from 150 to 400 mmol-SH/mol PLA when cystamine concentrations of 25-1518 mol cystamine/mol PLA were used during the thiolation reaction. In the second step, covalent coupling of antibodies to thiolated NPs (NPs-SH) was obtained via a bifunctional cross-linker, m-maleimidobenzoyl-N-hydroxy-sulfosuccinimide ester (sulfo-MBS). For both mAbs anti-HER2 and anti-CD20, respectively, the number of -SH functions on the NPs had no influence on the amount of mAb coupled to the NPs. Approximately, 295 anti-HER2 and 557 anti-CD20 molecules, respectively, were covalently coupled per nanoparticle. The NPs size after the coupling reactions was about 250 nm. The specific interaction between tumor cells and mAb-NPs was determined by confocal microscopy using two cell lines: SKOV-3 human ovarian cancer cells (overexpressing HER2) and Daudi lymphoma cells (overexpressing CD20). The results showed the selective targeting of mAb-NPs to tumor cells overexpressing the specific antigen. While anti-CD20 labeled NPs (anti-CD20 NPs) bound to and remained at the cellular surface, anti-HER2 labeled NPs (anti-HER2 NPs) were efficiently internalized. The mAb-NPs represent a promising approach to improve the efficacy of NPs in active targeting for cancer therapy while the choice of the antibody-target system defines the fate of the mAb-NPs after their binding to the cells.
Keywords
Antibodies, Monoclonal/*administration & dosage Antigens, CD20/immunology Antineoplastic Agents/*administration & dosage/chemistry Cell Line, Tumor Cross-Linking Reagents Drug Carriers/chemistry Drug Delivery Systems/*methods Female Humans Immunoconjugates/chemistry Lactic Acid Lymphoma/drug therapy Nanoparticles/chemistry/*therapeutic use Ovarian Neoplasms/drug therapy Polymers Receptor, erbB-2/immunology Sulfhydryl Compounds
Pubmed
Web of science
Create date
25/01/2008 11:28
Last modification date
20/08/2019 15:30
Usage data